Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	491.95M	105.77M	105.86M	166.36M	113.95M	173.24M	132.76M	151.21M	102.89M
Cost of Goods Sold	194.57M	52.20M	46.09M	61.26M	35.03M	73.83M	65.45M	80.33M	39.81M
Gross Profit	297.38M	53.58M	59.78M	105.11M	78.92M	99.41M	67.32M	70.88M	63.08M
Gross Profit Margin	60.4%	50.7%	56.5%	63.2%	69.3%	57.4%	50.7%	46.9%	61.3%
Total Operating Expenses	250.06M	65.41M	50.18M	56.90M	77.56M	81.36M	56.74M	57.40M	50.35M
Research & Development	137.67M	21.86M	24.51M	39.69M	51.61M	54.72M	38.17M	40.26M	33.57M
Selling, General & Administrative	114.83M	43.55M	25.67M	19.65M	25.95M	26.74M	18.61M	15.02M	16.88M
Operating Income (EBIT)	47.32M	-11.84M	9.59M	48.21M	1.36M	18.06M	10.58M	13.47M	12.73M
Operating Margin	9.6%	-11.2%	9.1%	29.0%	1.2%	10.4%	8.0%	8.9%	12.4%
Income Before Tax (EBT)	-32.16M	-66.76M	986K	39.65M	-6.03M	9.31M	93.42M	-44.44M	-24.75M
Interest Income	82.66M	N/A	33.41M	27.80M	21.44M	22.94M	126.31M	-153.58M	77.37M
Interest Expense	158.83M	41.02M	40.81M	40.74M	36.26M	36.65M	35.54M	-159.20M	90.68M
Other Income/Expense	-79.48M	-54.92M	-8.61M	-8.56M	-7.39M	-8.75M	82.84M	-57.91M	-37.48M
Net Income	-179.59M	-66.82M	1.03M	-108.58M	-5.22M	32.04M	109.68M	-66.97M	-11.39M
Income Tax Expense	147.43M	59K	-44K	148.23M	-813K	-22.73M	-16.26M	22.53M	-13.36M
Net Profit Margin	-36.5%	-63.2%	1.0%	-65.3%	-4.6%	18.5%	82.6%	-44.3%	-11.1%
EBITDA	80.67M	-1.51M	19.88M	58.62M	3.69M	26.95M	18.84M	21.63M	21.12M
EBITDA Margin	16.4%	-1.4%	18.8%	35.2%	3.2%	15.6%	14.2%	14.3%	20.5%
Depreciation & Amortization	33.35M	10.33M	10.29M	10.41M	2.32M	8.90M	8.26M	8.15M	8.40M
EPS Basic	-0.58	-0.19	0.00	-0.38	-0.02	0.11	0.39	-0.22	-0.04
EPS Diluted	-0.63	-0.19	0.00	-0.43	-0.02	0.10	0.35	-0.22	-0.04
Weighted Average Basic Shares	356.82M	356.82M	330.28M	279.19M	300.23M	281.23M	281.23M	301.81M	280.24M
Weighted Average Diluted Shares	356.82M	356.82M	330.28M	279.19M	300.23M	313.37M	313.37M	301.81M	280.24M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	586.32M	489.68M	91.43M	83.03M	36.77M	66.62M	31.92M
Cost of Goods Sold	235.56M	185.31M	160.86M	64.09M	0.00	0.00	0.00
Gross Profit	350.76M	304.37M	-69.42M	18.93M	36.77M	66.62M	31.92M
Gross Profit Margin	59.8%	62.2%	-75.9%	22.8%	100.0%	100.0%	100.0%
Total Operating Expenses	272.56M	234.73M	285.44M	365.38M	272.23M	204.15M	93.37M
Research & Development	184.19M	171.31M	210.83M	180.62M	191.01M	148.07M	95.56M
Selling, General & Administrative	90.95M	61.45M	73.04M	186.74M	84.13M	58.91M	48.57M
Operating Income (EBIT)	78.21M	69.64M	-354.86M	-346.44M	-235.46M	-137.54M	-61.45M
Operating Margin	13.3%	14.2%	-388.1%	-417.3%	-640.3%	-206.5%	-192.5%
Income Before Tax (EBT)	136.35M	-217.56M	-651.05M	-551.65M	-149.20M	-291.77M	-209.38M
Interest Income	198.49M	4.62M	4.82M	912K	19K	N/A	N/A
Interest Expense	149.19M	157.60M	134.82M	91.44M	112.97M	97.47M	95.75M
Other Income/Expense	58.14M	-287.21M	-296.19M	-205.21M	86.26M	-154.23M	-147.94M
Net Income	27.92M	-231.86M	-551.73M	-513.58M	-101.50M	-170.04M	-209.88M
Income Tax Expense	108.43M	14.30M	-99.32M	-38.07M	-47.69M	-121.73M	491K
Net Profit Margin	4.8%	-47.3%	-603.4%	-618.6%	-276.0%	-255.3%	-657.5%
EBITDA	116.06M	100.94M	-330.65M	-326.03M	-217.26M	-121.12M	-46.84M
EBITDA Margin	19.8%	20.6%	-361.6%	-392.7%	-590.8%	-181.8%	-146.8%
Depreciation & Amortization	37.85M	31.30M	24.21M	20.41M	18.20M	16.42M	14.61M
EPS Basic	0.10	-0.87	-2.43	-2.60	-3.25	-5.44	-0.86
EPS Diluted	0.10	-0.87	-2.43	-2.60	-3.25	-5.44	-0.86
Weighted Average Basic Shares	279.19M	267.92M	227.26M	197.72M	31.25M	31.25M	243.65M
Weighted Average Diluted Shares	279.19M	267.92M	227.26M	197.72M	31.25M	31.25M	243.65M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Luxembourg, LU

1,279 employees

www.alvotech.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Lisa Graver

View full financials